When Doctors Become Sales Reps: How Foreign Drug Companies Are Driving Deadly Prescriptions in Ghana

On most days in Accra, the system looks normal.

Patients line up. Doctors consult. Prescriptions are written. Pharmacies dispense. Life moves on.

But beneath that routine, an uncomfortable question is beginning to surface—one that few in Ghana’s healthcare system are willing to confront directly:

What happens when the doctor is no longer the final decision-maker, but the last link in a commercial chain?

Because that is where Ghana may be heading.

Quietly.

Without announcement.

Without resistance.

It starts long before a patient walks into the room.

Across hospitals and private clinics—from Osu to Tema, from Korle Bu to smaller district facilities—pharmaceutical representatives move through corridors with quiet familiarity. They are not strangers. They are expected. In many cases, they are welcomed.

They come representing companies—some local, many foreign, including firms linked to manufacturing hubs in India and the United States. They come with products doctors may not have deeply studied, molecules that are new to the market, brands competing aggressively for attention in a crowded pharmaceutical space.

They also come with strategy.

Conversations are brief but deliberate. A new drug is introduced. Its advantages are highlighted. Samples are left behind. A follow-up visit is scheduled. Over time, the product becomes familiar—not through independent clinical review, but through repeated exposure.

And familiarity, in medicine, is powerful.

Years ago, researchers at Kwame Nkrumah University of Science and Technology documented what many insiders already knew but rarely said openly: pharmaceutical representatives were visiting doctors regularly, offering samples, gifts, and building relationships that extended beyond the consulting room. Health professionals admitted that these interactions could influence what they prescribe, even as they insisted their judgment remained intact.

That tension—between perceived independence and actual influence—has never been resolved.

Fifteen years later, there has been no major national reassessment. No updated data to measure how deep this system now runs. No public registry of financial relationships between doctors and drug companies. No consistent monitoring of prescribing patterns.

What was once a warning has become a blind spot.

The problem is not that doctors are careless. The problem is that the system they operate in has quietly shifted.

In theory, every prescription should be grounded in evidence: clinical trials, treatment guidelines, patient history. In practice, another layer has been added—one driven by access, repetition, and commercial pressure.

A doctor does not need to be corrupt to be influenced. They only need to be human.

Repeated exposure to a drug name makes it easier to recall. A familiar representative becomes a trusted source. A product discussed weekly begins to feel safer than one rarely mentioned. Over time, that subtle shift can determine what ends up on a prescription pad.

And when those drugs originate from a complex global supply chain—manufactured abroad, marketed aggressively, and introduced rapidly into local markets—the risks multiply.

Ghana’s regulatory framework is not built for this level of complexity.

The Food and Drugs Authority is responsible for approving medicines and overseeing promotion. It vets advertisements, monitors safety reports, and enforces standards on paper. But the day-to-day interactions that shape prescribing decisions happen outside its direct line of sight.

There is limited visibility into how often doctors meet pharmaceutical representatives. Limited oversight of sponsored medical education. Limited tracking of how new drugs—especially those entering from international manufacturers—are adopted in clinical practice.

In effect, a critical part of the decision-making ecosystem operates without continuous scrutiny.

And that creates space.

That space is where risk grows.

Because not every drug aggressively promoted is fully understood by every prescriber. Not every new product has long-term safety data in the Ghanaian population. Not every recommendation shared in a short meeting reflects the full scientific picture.

Yet prescriptions are written.

Patients take the medicines.

And outcomes—good or bad—are absorbed quietly into the system.

This is where the conversation becomes uncomfortable, but necessary.

If a doctor is repeatedly exposed to products through representatives rather than independent research, at what point does prescribing become influenced selection? At what point does familiarity replace scrutiny? At what point does the system begin to resemble a marketplace more than a clinical environment?

These are not theoretical concerns. They are structural ones.

Because once prescribing patterns are shaped by commercial presence rather than purely clinical judgment, the consequences extend beyond individual patients.

Healthcare costs rise as branded drugs displace generics. Antibiotics risk being overused, feeding a global resistance crisis. Treatment decisions become less consistent, less predictable, and harder to audit.

Most importantly, trust begins to erode.

The silence around this issue is part of the problem.

Professional bodies like the Ghana Medical Association have not enforced a comprehensive, binding national framework governing interactions between doctors and pharmaceutical companies. Disclosure of financial relationships is not standard practice. Patients are not informed if a drug being prescribed is heavily promoted within the system.

So the burden falls on individuals—doctors to self-regulate, patients to trust, and regulators to react after the fact.

That is not a stable model.

What makes this situation particularly dangerous is not a single bad actor or a single unsafe drug. It is the quiet normalisation of influence in a system that depends on objectivity.

No alarms sound when a prescription is influenced. No warning appears on the paper handed to a patient. There is no visible signal that a decision may have been shaped by forces beyond the consultation room.

Everything looks routine.

Until it isn’t.

Accra Street Journal’s investigation is not an accusation against Ghanaian doctors. It is a warning about the environment surrounding them—one that is increasingly shaped by global pharmaceutical competition, aggressive marketing strategies, and regulatory gaps that have not kept pace.

Because if the current trajectory continues, the question will no longer be whether influence exists.

It will be how much of Ghana’s healthcare system has already adapted to it.

And that leads to a question every patient should now feel comfortable asking—without fear, without hesitation:

Is this medicine being prescribed because it is the best option… or because it is the most familiar one?

Until that question has a clear, transparent answer, the system remains exposed.

And the risk remains real.

FAQs

1. Are foreign pharmaceutical companies active in Ghana?
Yes. Many drugs in Ghana are manufactured or marketed by international companies, including those linked to India and the United States.

2. Do doctors always fully know every drug they prescribe?
Doctors rely on training and available information, but rapid product introduction and marketing can influence familiarity with certain drugs.

3. Is this illegal?
Not necessarily. Many interactions fall within regulatory grey areas.

4. Why is this a concern?
Because it can affect how medicines are chosen, potentially impacting safety, cost, and effectiveness.

5. What should patients do?
Ask questions about alternatives, costs, and why a specific drug is being prescribed.

References

1. KNUST. (2011). The Promotion of Prescription Medicines by Pharmaceutical Sales Representatives and Its Effects on Health Professionals in the Kumasi Metropolis.

2. National Institutes of Health. (2019). Table 1: Governance of Prescription Medicines – Ghana.

3. University of Ghana. (2022). Antimicrobial dispensing practices in medicine sales outlets in Greater Accra.

4. Ghanaian Times. (2019). FDA launches Code of Practice for sales guidelines.

5. GhanaWeb. (2019). FDA launches Code of Practice on sale of medical products.

6. AUDA-NEPAD-AMRH. Ghana regulatory profile.

7. GBC Ghana Online. (2022). Report advertisement which contravenes Schedule V diseases – FDA

Source: Accra Street Journal 

Last Updated on April 30, 2026 by Samuel Kwame Boadu

Samuel Kwame Boadu

Samuel Kwame Boadu is a Ghanaian media entrepreneur and storyteller with a passion for amplifying urban voices and uncovering everyday truths. He is the Editor-in-Chief and Founder of Accra Street Journal, a dynamic digital platform dedicated to capturing the pulse of Ghana’s capital—its people, culture, challenges, business, sports and innovations.

accrastreetjournal.com/